• HOME
  •  > 
  • 基礎医学
  •  > 
  • 免疫/血清
  •  >  エンドトキシン研究11　新生「日本エンドトキシン・自然免疫研究会」の発展を願って

エンドトキシン研究11　新生「日本エンドトキシン・自然免疫研究会」の発展を願って

出版社： 医学図書出版
著者：
発行日： 2009-11-07
分野： 基礎医学  >  免疫/血清
ISBN： 9784871513609
電子書籍版： 2009-11-07 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,100 円(税込)

購入する

商品紹介

本書は、去る2007年10月19日、20日の両日にわたって鹿児島市で開催された第13回日本エンドトキシン研究会の講演内容をまとめたものである。

目次

  • エンドトキシン研究11　
    新生「日本エンドトキシン・自然免疫研究会」の発展を願って

    ―目次―

    第1章　イブニングレクチャー「最近のトピックス」
    　1．坑炎症性脂質メディエーター　レゾルビンと炎症性肺疾患
    　2．ブレークスルー「新しい高感度エンドトキシン測定法の開発
    　　　―それでなにが分かるか？―」

    第2章　シンポジウム「敗血症ショックの治療標的」
    　侵襲に対する生体反応の予測と制御〜HMGB1を標的とした
    　　新たな治療戦略

    第3章　平成19年度日本エンドトキシン研究会奨励賞受賞講演
    　Endotoxin toleranceの機構解析とその臨床的応用に関する研究

    第4章　一般演題
    　1．MyD88およびIRAK-1によるNF-κBの活性化には異なる様式で
    　　　TRAF6が関与する
    　2．Toll-like receptor 4への作用が期待される
    　　　敗血症治療薬候補とリード化合物について
    　3．Campylobacter jejuni LPSと疾患との関わり合い
    　4．サルモネラのリポ多糖脱アシル化と抗菌ペプチド抵抗性
    　5．LPS刺激によるToll-like receptor(TLR)を介した
    　　　IL-18ならびにIL-1βの分泌
    　6．熱ショック蛋白質（HSP）のToll-like リセプターアゴニスト
    　　　作用と坑HSP自己抗体による増強作用
    　7．Cathelicidinファミリーの生体防御ペプチドCAP11を用いた
    　　　敗血症性メディエーターの制御
    　8．致死的メディエーター対策としてのステロイドの可能性

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.3 掲載の参考文献
1) Iso H, Kobayashi M, Ishihara J, et al. : Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese : the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 113 : 195-202, 2006
PubMed
2) Yokoyama M, Origasa H, Matsuzaki M, et al. : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007
PubMed
3) Serhan CN, Clish CB, Brannon J, et al. : Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 : 1197-1204, 2000
PubMed
4) Serhan CN, Arita M, Hong S, et al. : Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspir-in-triggered epimers. Lipids 39 : 1125-1132, 2004
 
5) Arita M, Yoshida M, Hong S, et al. : Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102 : 7671-7676, 2005
PubMed
6) Hasturk H, Kantarci A, Ohira T, et al. : RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis. FASEB J 20 : 401-403, 2006
 
7) Arita M, Bianchini F, Aliberti J, et al. : Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201 : 713-722, 2005
PubMed
8) Arita M, Ohira T, Sun YP, et al. : Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178 : 3912-3917, 2007
PubMed
9) Haworth O, Cernadas M, Yang R, et al. : Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation, Nat Immunol 9 : 873-879, 2008
PubMed
10) Kennedy JI Jr., Chandler DB, Fulmer JD, et al. : Dietary fish oil inhibits bleomycin-induced pulmonary fibrosis in the rat. Exp Lung Res 15 : 315-329, 1989
PubMed
P.8 掲載の参考文献
1) 丸山征郎 : 生体反応の相互関連. 救急医学 30 : 1021-1024, 2006
 
2) Bone RC, Fein AM, Balk RA, et al. : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 : 1644-1655, 1992
PubMed
3) 井上一知, 瀬戸山博, 今村正之 : 臓器相関. 小川道雄, 斎藤英昭編, 臨床侵襲学. へるす出版 1998, p434-441
 
4) Yang H, Ochani M, Li J, et al. : Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101 : 296-301, 2004
PubMed
5) Wang H, Yang H, Tracey KJ : Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255 : 320-331, 2004
 
6) Wang H, Bloom O, Zhang M, et al. : HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 : 248-251, 1999
PubMed
7) 丸山征郎 : 炎症とHMGB1/RAGEシステム. 血管医学 6 : 519-523, 2005
Medical*Online
8) DeMarco RA, Fink MP, Lotze MT : Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 42 : 433-444, 2005
 
9) Rovere-Querini P, Capobianco A, Scaffidi P, et al. : HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5 : 825-830, 2004
PubMed
10) Klune JR, Billiar TR, Tsung A : HMGB1 preconditioning : therapeutic apPlication for a danger signal? J Leukoc Biol 83 : 558-563, 2008
PubMed
11) Harris HE, Raucci A : Alermin (g) news about danger : Workshop on innate danger signals and HMGB1. EMBO Rep 7 : 774-778, 2006
PubMed
12) Abeyama K, Stern DM, Ito Y, et al. : The N-terminal domain of thrombomodulin sequesters high mobility group-B1 protein. J Clin Invest 115 : 1267-1274, 2005
 
13) Ito T, Kawahara K, Okamoto K, et al. : Proteolytic cleavage of high mobility group box 1 protein by thrombn-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28 : 1825-1830, 2008
 
14) Suda K, Kitagawa Y, Ozawa S, et al. : Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy : a predictor of clinical course after surgery? Dis Esophagus 19 : 5-9, 2006
 
15) Hatada T, Wada H, Nobori T, et al. : Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94 : 975-979, 2005
PubMed
16) Ellerman JE, Brown CK, deVera M, et al. : Masquerader : High Mobility Group Box-1 and Cancer. Clin Cancer Res 13 : 2836-2848, 2007
 
17) Ulloa L, Ochani M, Yang H, et al. : Ethyl pyruvate protects lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99 : 12351-12356, 2002
PubMed
18) Wang H, Liao H, Ochani M, et al. : Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10 : 1216-1221, 2004
PubMed
19) Chen G, Li J, Qiang X, et al. : Suppression of HMGB-1 release by stearoyl lysophosphatidylcholine : an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46 : 623-627, 2005
 
20) Mollica L, De Marchis F, Spitaleri A, et al. : Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14 : 431-441, 2007
PubMed
21) Suda K, Kitagawa Y, Ozawa S, et al. : Neutrophil elastase inhibitor improves postoperative clinical courses after thoracic esophagectomy. Dis Esophagus 20 : 478-486, 2007
PubMed
22) Hagiwara S, Iwasaka H, Noguchi T : Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. J Anesth 21 : 164-170, 2007
PubMed
23) Hagiwara S, Iwasaka H, Matsumoto S, et al. : High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 34 : 218-221, 2008
 
24) Hagiwara S, Iwasaka H, Hasegawa A, et al. : High-dose intravenous immunoglobulin G improves systemic infiammation in a rat model of CLP-induced sepsis. Intensive Care Med 34 : 1812-1819, 2008
 
25) Suda K, Kitagawa Y, Ozawa S, et al. : Anti-highmobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 30 : 1-8, 2006
PubMed
26) Lutterloh EC, Opal SM, Pittman DD, et al. : Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 11 : R122, 2007
PubMed
27) Bianchi ME : DAMPs, PAMPs and alarmins : all we need to know about danger. J Leukoc Biol 81 : 1-5, 2007
 
P.15 掲載の参考文献
1) Members of the American College of Chest Physician/Society of Critical Care Medicine Consensus Committee : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992
 
2) Beeson PB : Tolerance to bacterial pyrogens. J Exp Med 86 : 29-38, 1947
PubMed
3) Hiki N, Mimura Y, Hatao F, et al. : Sublethal endotoxin administration evokes super-resistance to systemic hypoxia in rats. J Trauma 54 : 584-589, 2003
PubMed
4) Neviere RR, Cepinskas G, Madorin WS, et al. : LPS pretreatment ameliorates peritonitis-induced myocardial inflammation and dysfunction : role of myocytes. Am J Physiol 277 : H885-892, 1999
PubMed
5) Barroso-Aranda J, Chavez-Chavez RH, Mathison JC, et al. : Circulating neutrophil kinetics during tolerance in hemorrhagic shock using bacterial lipopolysaccharide. Am J physiol 266 : H415-421, 1994
PubMed
6) Remi RN, FuYan L, Tejdip S : Endotoxin induces adose-dependent myocardial cross-tolerance to ischemia-reperfusion injury. Crit Care Med 28 : 1439-1444, 2000
 
7) Wang JH, Doyle M, Manning BJ : Cutting edge : Bacterial lipoprotein induces endotoxin-independent tolerance to septic shock. J Immunol 170 : 14-18, 2003
PubMed
8) Yeo SJ, Yoon JG, Hong SC, et al. : CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNA and lipopolysaccharide : alterations in IL-1 receptorassociated kinase expression. J Immunol 170 : 1052-1061, 2003
PubMed
9) 畑尾史彦, 室井正志, 棚元憲一, 他 : エンドトキシン活性に及ぼすToll-like receptor刺激薬によるcross toleranceの効果. 日本エンドトキシン研究会編, エンドトキシン研究 7. 医学図書出版 2004, p117-122
 
10) Hatao F, Muroi M, Ogawa T, et al. : Prolonged Toll-like receptor stimulation leads to downregulation of IRAK-4 protein. J Leukoc Biol 76 (4) : 904-908, 2004
 
11) Hatao F, Hiki N, Mimura Y, et al. : The induction of super-resistance using synthetic lipopolysaccharide receptor agonist rescues fatal endotoxemia in rats without excessive immunosuppression. Shock 23 (4) : 365-370, 2005
PubMed
P.19 掲載の参考文献
1) Li S, Strelow A, Fontana EJ, et al. : IRAK-4 : a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 99 : 5567-5572, 2002
PubMed
2) Cao Z, Xiong J, Takeuchi M, et al. : TRAF6 is a signal transducer for interleukin-1. Nature 383 : 443-446, 1996
PubMed
3) Fujihara M, Muroi M, Tanamoto K, et al. : Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide : roles of the receptor complex. Pharmacol Ther 100 : 171-194, 2003
PubMed
4) Deng L, Wang C, Spencer E, et al. : Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 : 351-361, 2000
 
5) Baud V, Liu ZG, Bennett B, et al. : Signaling by proinflammatory cytokines : oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev 13 : 1297-1308, 1999
PubMed
6) Muroi M, Tanamoto K : TRAF6 distinctively mediates MyD88-and IRAK-1-induced activation of NF-κB. J Leukoc Biol 83 : 702-707, 2008
 
P.21 掲載の参考文献
1) Yamada M, Ichikawa T, Ii M, et al. : Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents : synthesis and biological activity of alkyl 6- (N-substituted sulfamoyl) cyclohex-1-ene-1-carboxylate. J Med Chem 48 : 7457-7467, 2005
PubMed
2) Ii M, Matsunaga N, Hazeki K, et al. : A novel cyclohexene derivative, ethyl (6R) -6- [N- (2-Chloro-4-fluorophenyl) sulfamoyl］cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through supPression of intracellular signaling. Mol Pharmacol 69 : 1288-1295, 2005
PubMed
3) Kawamoto T, Ii M, Kitazaki T, et al. : TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 584 : 40-48, 2008
PubMed
4) Sugiyama K, Muroi M, Tanamoto K : A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-κB and in vivo toxicity. Eur J Pharmacol 594 : 152-156, 2008
 
5) Yang QW, Mou L, Lv FL : Novel TLR4-antagonizing Peptides inhibit LPS-induced release of inflammatory mediators by monocytes. Biochem Biophys Res Commun 329 : 846-854, 2005
PubMed
P.25 掲載の参考文献
1) Tholozan JL, Cappelier JM, Tissier Jp, et al. : Physiological characterization of viable-but-nonculturable Campylobacter jejuni cells. Appl Environ Microbiol 65 : 1110-1116, 1999
PubMed
2) 三澤尚明 : カンピロバクター感染症の新展開. 日本食品微生物学会雑誌 20 : 91-97, 2003
Medical*Online
3) Skirrow WB, Blaser MJ : Clinical aspects of Campylobacter infection. In "Campylobacter" 2nd Edition, eds Nachamkin I, Blaser MJ, ASM Press, Washington DC, 2000, p69-88
 
4) Kuroki S, Saida T, Nukina M, et al. : Campylobacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 33 : 243-247, 1993
 
5) Misawa N, Blazer MJ : Detection and autoagglutination activity by Campylobacter jejuni. Infect Immun 68 : 6168-6175, 2000
 
6) 柴田淑子, 笠原由美子, 天野憲一 : 培養条件におけるCampylobacter jejuniとCampylobacter coliの形態変化とそれに伴う菌体成分の比較. 日本細菌学雑誌 46 : 921-927, 1991
 
P.28 掲載の参考文献
1) Groisman EA : The pleiotropic two-component regulatory system PhoP-PhoQ. J Bacteriol 183 : 1835-1842, 2001
PubMed
2) Kawasaki K, Ernst RK, Miller SI : Inhibition of Salmonella enterica serovar Typhimurium lipopolysaccharide deacylation by aminoarabinose membrane modification. J Bacteriol 187 : 2448-2457, 2005
PubMed
3) Kawasaki K, China K, Nishijima M : Release of the lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to the antimicrobial peptide polymyxin B in Salmonella enterica. J Bacteriol 189 : 4911-4919, 2007
 
P.31 掲載の参考文献
1) Akira S, Uematsu S, Takeuchi O : Pathogen recognition and innate immunity. Cell 124 : 783-801, 2006
PubMed
2) Nakanishi K, Yoshimoto T, Tsutsui H, et al. : Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19 : 423-474, 2001
 
3) Tsutsui H, Yoshimoto T, Hayashi N, et al. : Induction of allergic infiammation by interleukin-18 in experimental animal models. Immunol Rev 202 : 115-138, 2004
 
4) Martinon F, Tschopp J : Inflammatory caspases and inflammasomes : master switches of inflammation. Cell Death Differ 14 : 10-22, 2007
 
5) Mariathasan S, Monack DM : Inflammasome adaptors and sensors : intracellular regulators of infection and inflammation. Nat Rev Immunol 7 : 31-40, 2007
PubMed
6) Tsutsui H, Matsui K, Okamura H, et al. : Pathophysiological roles of interleukin-18 for inflammatory liver diseases. Immunol Rev 174 : 192-209, 2000
PubMed
7) Imamura M, Tsutsui H, Yasuda K, et al. : Contribution of TIR domain-containing adapter inducing IFN-b-mediated IL-18 release to LPS-induced liver injury in mice. J Hepatol : In Press, 2009
 
P.35 掲載の参考文献
1) Tishler M, Shoenfeld Y : Anti-heat-shock protein antibodies in rheumatic and autoimmune diseases. Semin Arthritis Rheum 26 : 558-563, 1996
PubMed
2) Yokota S, Minota S, Fujii N : Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 18 : 573-580, 2006
PubMed
3) Calderwood SK, Mambula SS, Gray Jr PJ, et al : Extracellular heat shock proteins in cell signaling. FEBS Lett 581 : 3689-3694, 2007
 
4) Binder RJ, Vatner R, Srivastava P : The heat-shock protein receptors : some answers and more questions. Tissue Antigen 6 : 442-451, 2004
 
5) Multhoff G : Heat shock proteins in immunity. In "Handbook of Experimental Pharmacology vol. 172 Molecular Chaperones in Health and Diseases" eds Matthias G, Springer-Verlag, Berlin, 2006, p279-304
 
P.40 掲載の参考文献
1) Gennaro R, Zanetti M : Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 55 : 31-49, 2000
PubMed
2) Yomogida S, Nagaoka I, Yamashita T : Comparative studies on the extracellular release and biological activity of guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP11) and defensins. Comp Biochem Physiol B Biochem Mol Biol 116 : 99-107, 1997
PubMed
3) Nagaoka I, Tsutsumi-lshii Y, Yomogida S, et al. : Isolation of cDNA encoding guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP11) and evaluation of CAP11 mRNA expression during neutrophil maturation. J Biol Chem 272 : 22742-22750, 1997
 
4) Nagaoka I, Hirota S, Niyonsaba F, et al. : Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14 (+) cells. J Immunol 167 : 3329-3338, 2001
 
5) Nagaoka I, Hirota S, Yomogida S, et al. : Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 49 : 73-79, 2000
PubMed
6) Wang H, Yang H, Czura CJ, et al. : HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164 : 1768-1773, 2001
 
7) Varga K, Wagner JA, Bridgen DT, et al. : Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. Faseb J 12 : 1035-1044, 1998
PubMed
8) Hasunuma R, Maruyama H, Takimoto H, et al. : Does high mobility group 1 protein function as a late mediator for LPS-or TNF-induced shock in galactosamine-sensitized mice? J Endotoxin Res 8 : 391-398, 2002
PubMed
9) Wang H, Bloom O, Zhang M, et al. : HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 : 248-251, 1999
PubMed
10) Roche M, Kelly JP, O'Driscoll M, et al. : Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 125 : 263-271, 2008
PubMed
P.44 掲載の参考文献
1) Roger CB, Charles JE Terry P. C, et al. : A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock N Engl J Med 317 : 653-658, 1987
 
2) Dellinger RP, Levy MM, Carlet JM, et al : Surviving Sepsis Campaign : international guidelines for management of severe sepsis and septic shock : 2008. Crit Care Med 36 : 296-327, 2008
PubMed
3) 丸山征郎 : エンドトキシンショックにおけるパラダイムシフト-早期メディエータ : アナンダマイドと後期メディエータ : HMG-1. 臨床麻酔 24 (9) : 1477-1485, 2000
 
4) Wang Y, Liu Y, Sarker KP, et al. : Polymyxin B binds to anandamid and inhibits its cytotoxic efect. FEBS Lett 470 : 151-155, 2000
 
5) Tsuneto S, lkenaga M, Hosoi J, et al. : Malignant intestinal obstruction. Eguchi K, Klastersky J, Feld R eds, Current Perspectives and Future Directions in Palliative Medicine. Springer-Verlag, 1998, p25-32.
 
6) Jones DP, Mahmound H, Chesney RW : Tumor lysis syndrome : pathogenesis and management. Pdiatric Nephrology 9 : 206-208, 1995
 

書評

最近チェックした商品履歴

Loading...